Contact this trialFirst, we need to learn more about you.
XPO1 inhibitor
KPT-8602 for Multiple Myeloma
Recruiting1 awardPhase 1 & 2
Austin, Texas
This trial will assess the safety, tolerability, and preliminary efficacy of KPT-8602, an oral XPO1 inhibitor, in patients with relapsed/refractory multiple myeloma, metastatic colorectal cancer, metastatic castration resistant prostate cancer, higher risk myelodysplastic syndrome, acute myeloid leukemia, and newly diagnosed intermediate/high-risk MDS.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.